References
- 1. S. Kantipudi and A. Khasnis, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme, Cong. Heart Fail.10 (2004) 114–116; https://doi.org/10.1111/j.1527-5299.2004.02799.x
- 2. R. Vellalacheruvu, R. S. Leela, L. K. Ravindranath and M. Thummisetty, Novel route for synthesis of antihypertensive activity of tetrazole analogues as a carbamate and urea derivatives, Org. Med. Chem. IJ.3 (2017) Article ID 555609 (10 pages); https://doi.org/10.19080/OMCIJ.2017.03.555609
- 3. The International Council for Harmonisation (ICH), Q3A(R2) Guideline. Impurities in New Drug Substances, October 2006; http://www.ich.org/products/guidelines/quality/quality-single/article/impurities-in-new-drug-substances.html; last access March 24, 2018.
- 4. D. J. Snodin and S. D. McCrossen, Mutagenic impurities in pharmaceuticals. A critique of the derivation of the cancer TTC (Threshold of Toxicological Concern) and recommendations for structural-class-based limits, Regul. Toxicol. Pharm.67 (2013) 299–316; https://doi.org/10.1016/j.yrtph.2013.08.014
- 5. S. Singh, T. Handa, M. Narayaaani, A. Sahu, M. Junwal and R. P. Shah, A critical review on the use of modem sophisticated hyphenated tools in the characterization of impurities and degradation products, J. Pharm. Biomed. Anal.69 (2012) 148–173; https://doi.org/10.1016/j.jpba.2012.03.044
- 6. S. Mehta, R. P. Shah, R. Priyadarshi and S. Singh, LC and LC–MS/TOF studies on stress degradation behaviour of candesartan cilexetil, J. Pharm. Biomed.52 (2010) 345–354; https://doi.org/10.1016/j.jpba.2009.05.006
- 7. S. Sangwan, T. Panda, K. Nayyar, S. K. Dewan and R. K. Thaper, Synthesis and characterization of impurities of a common and advanced intermediate of candesartan and azilsartan antihypertensive drugs, Int. Res. J. Pure Appl. Chem.5 (2015) 140–149; https://doi.org/10.9734/irjpac/2015/13162
- 8. B. Raman, B. A. Sharma, G. Mahale, D. Singh and A. Kumar, Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR, J. Pharm. Biomed.56 (2011) 256–263; https://doi.org/10.1016/j.jpba.2011.05.024
- 9. N. A. Kakasaheb, K. Ramakrishna and V. Srinivasarao, Method development and validation by GC-MS for quantification of 1-chloroethyl cyclohexyl carbonate as a genotoxic impurity in candesartan cilexetil drug substance, Int. J. Pharm. Pharm. Sci.6 (2014) 370–372.
- 10. D. Henschler, Toxicity of chlorinated organic compounds: effects of the introduction of chlorine in organic molecules, Angew. Chem. Int. Ed.33 (1994) 1920–1935; https://doi.org/10.1002/anie.199419201
- 11. J.-P. Senet, G. Sennyey and G. P. Wooden, A convenient new route to 1-haloalkyl carbonates, Synthesis5 (1988) 407–410; https://doi.org/10.1055/s-1988-27596
- 12. Y. V. Shurukhin, N. A. Klyuev and I. I. Grandberg, Similarities between thermolysis and mass spectrometric fragmentation of tetrazoles (review), Chem. Heterocyc. Compd.21 (1985) 605–620.
- 13. M. Peng, S. Li, J. Wu, Y. Guo, S. Cao and Y. Zhao, Fragmentation studies of sartans by electrospray ionization mass spectrometry, J. Mass Spectrom.52 (2017) 591–596; https://doi.org/10.1002/jms.3965
- 14. I. Dams, A. Ostaszewska, M. Puchalska, J. Chmiel, P. Cmoch, I. Bujak, A. Białońska and V. J. Szczepek, Synthesis and physicochemical characterization of the process-related impurities of olmesartan medoxomil. Do 5-(biphenyl-2-yl)-1-triphenylmethyltetrazole intermediates in sartan syntheses exist?, Molecules20 (2015) 21346–21363; https://doi.org/10.3390/molecules201219762